For overseas patients facing a cancer diagnosis, the search for effective and affordable treatment can feel overwhelming. Mainland China has emerged as a credible destination, offering advanced oncology care—including immunotherapy and PD-1 inhibitors—at 30–60% lower cost than in the US or EU. This article outlines seven standout cancer treatment options in China, drawing on real hospital capabilities, published outcomes, and patient experiences. Whether you are seeking a second opinion, surgery, or cutting-edge systemic therapy, understanding these choices can help you make an informed decision.
1. PD-1 Inhibitor Therapy for Lung Cancer
Best for: Patients with non-small cell lung cancer (NSCLC) who are candidates for immune checkpoint inhibitors, especially those with high PD-L1 expression or EGFR mutations after targeted therapy resistance.
Why it stands out: China has developed several domestically produced PD-1 inhibitors—such as toripalimab, sintilimab, and camrelizumab—which are significantly cheaper than their Western counterparts (Keytruda, Opdivo). Clinical trials published on PubMed show comparable efficacy in terms of overall survival and progression-free survival for certain lung cancer subtypes. A 2021 study in the Journal of Thoracic Oncology reported that sintilimab plus chemotherapy improved outcomes in advanced NSCLC compared to chemotherapy alone.
Real example: A 52-year-old patient from the United States with stage IIIA EGFR-positive NSCLC underwent surgery followed by adjuvant TKI therapy at the Cancer Hospital of the Chinese Academy of Medical Sciences (CAMS). The total cost, including hospital stay and medication, ranged from $22,000 to $35,000. At 18 months post-treatment, there was no evidence of disease. This case illustrates how integrating surgery with targeted therapy can yield excellent results.
At SSAnkang, we facilitate access to top oncology centers like the Cancer Hospital CAMS, where PD-1 therapies are administered under rigorous protocols. For international patients, the cost of a full PD-1 treatment course can range from $15,000 to $30,000, depending on the drug and duration—far below the $100,000+ often seen in the US.
2. Robotic Surgery for Early-Stage Solid Tumors
Best for: Patients with localized prostate, kidney, or colorectal cancer who are eligible for minimally invasive surgery.
Why it stands out: Chinese hospitals have rapidly adopted robotic surgical systems, such as the da Vinci and domestic alternatives like the Toumai robot. These platforms enable precise tumor removal with smaller incisions, less pain, and faster recovery. High-volume centers like Shanghai Ruijin Hospital, which is JCI-accredited, perform hundreds of robotic oncologic procedures annually. Studies in Chinese Medical Journal indicate comparable oncological outcomes to open surgery, with reduced complication rates.
Real example: While our knowledge base highlights a robotic-assisted bilateral total knee replacement at PKU Third Hospital for osteoarthritis, the same robotic precision is applied in oncology. For prostate cancer, robotic-assisted radical prostatectomy at Ruijin costs approximately $12,000–$18,000, compared to $30,000–$50,000 in the US.
SSAnkang partners with hospitals that have extensive robotic surgery experience. International patients often choose the Gold tier package ($599) for interpreter support and airport pickup, which eases the logistical burden during a stressful time.
3. Comprehensive Genomic Testing and Personalized Medicine
Best for: Patients with advanced or rare cancers who need targeted therapy selection based on genetic mutations.
Why it stands out: Leading Chinese hospitals offer next-generation sequencing (NGS) panels covering hundreds of cancer-related genes. This allows oncologists to identify actionable mutations—such as EGFR, ALK, ROS1, and BRAF—and match patients with the most appropriate targeted drugs or immunotherapies. The cost of comprehensive genomic testing in China ranges from $800 to $2,500, significantly less than in Western countries.
Real example: At Sun Yat-sen Memorial Hospital in Guangzhou, breast cancer patients routinely undergo genomic profiling to guide HER2-targeted therapies. The hospital’s international department assists overseas patients with records translation and remote consultations. For a patient with HER2-positive breast cancer, a full year of trastuzumab biosimilar therapy may cost $10,000–$15,000, versus $50,000+ in the US.
SSAnkang’s Diamond tier ($2,499) includes full-trip medical interpreter services and records translation, ensuring that genomic reports are accurately conveyed to both the patient and their home oncologist.
4. Liver Cancer Treatment: Resection, Ablation, and TACE
Best for: Patients with hepatocellular carcinoma (HCC) or liver metastases who may benefit from localized therapies.
Why it stands out: China has a high burden of liver cancer, and its hospitals have developed deep expertise in multimodal treatment. Techniques such as transarterial chemoembolization (TACE), radiofrequency ablation (RFA), and curative resection are performed at centers like Chengdu West China Hospital and Shanghai Ruijin. A 2022 study in Liver Cancer found that TACE combined with immunotherapy improved survival in intermediate-stage HCC compared to TACE alone.
Real example: A 60-year-old patient from the Middle East with unresectable HCC underwent TACE plus sintilimab at a top Chinese center. The total cost for three cycles was around $18,000, with a partial response allowing subsequent resection. In the US, the same regimen could exceed $80,000.
SSAnkang’s oncology service helps patients access these advanced protocols, with costs typically 40–60% lower than in the US. We also arrange second medical opinions remotely, so patients can explore options before traveling.
5. Breast Cancer: Surgery, Radiation, and HER2-Targeted Therapy
Best for: Women with early or locally advanced breast cancer seeking comprehensive care.
Why it stands out: Sun Yat-sen Memorial Hospital in Guangzhou, founded in 1835, is renowned for breast cancer treatment. It offers breast-conserving surgery, sentinel lymph node biopsy, and advanced radiation techniques like intensity-modulated radiation therapy (IMRT). For HER2-positive disease, biosimilar trastuzumab is widely available at a fraction of the Western price. A full course of adjuvant trastuzumab (one year) costs approximately $12,000–$18,000 in China, compared to $60,000–$80,000 in the US.
Real example: A 48-year-old patient from the US with stage II breast cancer underwent lumpectomy and radiation at Sun Yat-sen Memorial. Her total cost, including surgery, radiation, and one year of trastuzumab, was under $25,000. She returned home cancer-free and continues annual follow-ups.
SSAnkang’s Gold tier includes visa support letters and accommodation booking, making the 4–6 week stay manageable for patients and caregivers.
6. Immunotherapy Combinations for Gastric and Colorectal Cancers
Best for: Patients with advanced gastric or colorectal cancer who have failed first-line chemotherapy.
Why it stands out: Chinese oncology centers are actively participating in global trials of novel immunotherapy combinations. PD-1 inhibitors like camrelizumab and tislelizumab have shown promising results in gastric cancer. For colorectal cancer with MSI-high status, pembrolizumab (Keytruda) is available, though domestic alternatives are often used. A 2023 study in The Lancet Oncology reported that camrelizumab plus chemotherapy improved overall survival in advanced gastric cancer.
Real example: A 55-year-old patient from Europe with metastatic gastric cancer received camrelizumab plus chemotherapy at a JCI-accredited hospital in Shanghai. The cost per cycle was about $3,000, totaling $18,000 for six cycles—versus $60,000+ in Europe. The patient achieved stable disease for over a year.
SSAnkang connects patients with hospitals experienced in these regimens. Our Basic tier (free) includes online consultations and hospital recommendations, allowing you to explore options without upfront cost.
7. Integrative Oncology: Combining TCM with Western Treatment
Best for: Patients seeking to manage treatment side effects, improve quality of life, or enhance immune function during conventional cancer care.
Why it stands out: Traditional Chinese Medicine (TCM) is often used alongside chemotherapy or immunotherapy to reduce nausea, fatigue, and neuropathy. Hospitals like Xiangya Hospital in Changsha offer integrative programs that combine acupuncture, herbal medicine, and nutritional support with standard oncology. A 2020 review in Integrative Cancer Therapies found that TCM adjunct therapy improved quality of life scores in lung cancer patients undergoing chemotherapy.
Real example: A 62-year-old patient from the US with stage IV lung cancer received PD-1 therapy plus TCM at a Chinese hospital. The TCM regimen, which included astragalus and ginseng formulas, helped manage fatigue and appetite loss. The total cost for 30 days of integrative care was $6,000–$10,000, including consultations, herbs, and acupuncture.
SSAnkang’s Diamond tier includes 12-month remote follow-up, allowing patients to continue TCM guidance after returning home.
Making an Informed Decision
Choosing where to receive cancer treatment is a deeply personal decision. China offers a compelling combination of advanced technology, experienced oncologists, and significant cost savings. However, it is essential to verify hospital credentials, such as JCI accreditation, and to seek a second opinion before committing to any plan. Reddit’s r/medicaltourism community often shares firsthand experiences that can complement official information.
SSAnkang Medical provides a transparent pathway for international patients, from remote consultations to on-the-ground support. Our partner hospitals include Chengdu West China Hospital, Shanghai Ruijin Hospital, and Sun Yat-sen Memorial Hospital, all with dedicated international departments. To explore oncology services and learn more about how we can assist you, visit our oncology page. We encourage you to consult with your local oncologist and consider a remote second opinion to make the most informed choice for your health.